Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prospective observational study of T-DM1 in HER2-positive advanced breast cancer
ChiCTR2300077438Phase 4Not yet recruiting
- Sponsor
- Army Medical Center of PLA
- Start
- Nov 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Army Medical Center of PLA. Primary endpoint: Real-world progression-free survival (rwPFS). Planned start Nov 2023; status: not yet recruiting.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2300077438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077438.